SMT201800492T1 - Dosaggio orale di composti di glp-1 - Google Patents

Dosaggio orale di composti di glp-1

Info

Publication number
SMT201800492T1
SMT201800492T1 SM20180492T SMT201800492T SMT201800492T1 SM T201800492 T1 SMT201800492 T1 SM T201800492T1 SM 20180492 T SM20180492 T SM 20180492T SM T201800492 T SMT201800492 T SM T201800492T SM T201800492 T1 SMT201800492 T1 SM T201800492T1
Authority
SM
San Marino
Prior art keywords
glp
compounds
oral dosing
dosing
oral
Prior art date
Application number
SM20180492T
Other languages
English (en)
Italian (it)
Inventor
Per Sauerberg
Flemming Seier Nielsen
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48190381&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SMT201800492(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of SMT201800492T1 publication Critical patent/SMT201800492T1/it

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
SM20180492T 2013-05-02 2014-05-02 Dosaggio orale di composti di glp-1 SMT201800492T1 (it)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP13166205 2013-05-02
EP14721834.1A EP2991671B1 (en) 2013-05-02 2014-05-02 Oral dosing of glp-1 compounds
PCT/EP2014/058974 WO2014177683A1 (en) 2013-05-02 2014-05-02 Oral dosing of glp-1 compounds

Publications (1)

Publication Number Publication Date
SMT201800492T1 true SMT201800492T1 (it) 2018-11-09

Family

ID=48190381

Family Applications (1)

Application Number Title Priority Date Filing Date
SM20180492T SMT201800492T1 (it) 2013-05-02 2014-05-02 Dosaggio orale di composti di glp-1

Country Status (25)

Country Link
US (5) US20160067184A1 (OSRAM)
EP (2) EP3485900A1 (OSRAM)
JP (2) JP6672140B2 (OSRAM)
KR (3) KR20210086717A (OSRAM)
AU (1) AU2014261336B2 (OSRAM)
BR (1) BR112015026325A2 (OSRAM)
CA (1) CA2910903A1 (OSRAM)
CY (1) CY1120730T1 (OSRAM)
DK (1) DK2991671T3 (OSRAM)
ES (1) ES2688462T3 (OSRAM)
HR (1) HRP20181393T1 (OSRAM)
HU (1) HUE040609T2 (OSRAM)
IL (1) IL241813A (OSRAM)
LT (1) LT2991671T (OSRAM)
MX (3) MX369259B (OSRAM)
MY (1) MY172578A (OSRAM)
PL (1) PL2991671T3 (OSRAM)
PT (1) PT2991671T (OSRAM)
RS (1) RS58039B1 (OSRAM)
RU (1) RU2671406C2 (OSRAM)
SA (1) SA515370075B1 (OSRAM)
SI (1) SI2991671T1 (OSRAM)
SM (1) SMT201800492T1 (OSRAM)
WO (1) WO2014177683A1 (OSRAM)
ZA (2) ZA201507096B (OSRAM)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3326620T3 (pl) 2010-12-16 2020-08-24 Novo Nordisk A/S Kompozycje stałe zawierające agonistę glp-1 i sól kwasu n-(8-(2- hydroksybenzoilo)amino)kaprylowego
BR112013026195A2 (pt) 2011-04-12 2016-11-29 Novo Nordisk As derivados de glp-1 duplamente acilados
CN111494323B (zh) 2012-03-22 2023-03-28 诺和诺德股份有限公司 包含递送剂的组合物及其制备
DK2827845T3 (en) 2012-03-22 2019-04-01 Novo Nordisk As COMPOSITIONS INCLUDING A PROCEDURE AND PREPARING THEREOF
HUE062740T2 (hu) 2012-03-22 2023-12-28 Novo Nordisk As GLP-1 peptidek készítményei és elõállításuk
US9993430B2 (en) 2012-06-20 2018-06-12 Novo Nordisk A/S Tablet formulation comprising semaglutide and a delivery agent
PT2991671T (pt) * 2013-05-02 2018-11-05 Novo Nordisk As Dosagem oral de compostos de glp-1
AU2016206950B2 (en) 2015-01-12 2021-05-06 Enteris Biopharma, Inc. Solid oral dosage forms
CN107205948B (zh) 2015-01-29 2021-12-14 诺和诺德股份有限公司 包含glp-1激动剂和肠溶衣的片剂
WO2016168388A2 (en) 2015-04-14 2016-10-20 Palatin Technologies, Inc. Therapies for obesity, diabetes and related indications
US11196462B2 (en) * 2016-02-22 2021-12-07 Qualcomm Incorporated Multi-layer beamforming in millimeter-wave multiple-input/multiple-output systems
JP6633777B2 (ja) 2017-08-24 2020-01-22 ノヴォ ノルディスク アー／エス Ｇｌｐ−１組成物及びその使用
MA50358A (fr) * 2017-10-12 2020-08-19 Novo Nordisk As Sémaglutide en thérapie médicale
CR20200185A (es) * 2017-10-31 2020-06-19 Medimmune Ltd Administración oral de análogos del péptido glp-1
SG11202006595RA (en) * 2018-02-02 2020-08-28 Novo Nordisk As Solid compositions comprising a glp-1 agonist, a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid and a lubricant
TWI829687B (zh) 2018-05-07 2024-01-21 丹麥商諾佛 儂迪克股份有限公司 包含glp-1促效劑與n-(8-(2-羥基苯甲醯基)胺基)辛酸之鹽的固體組成物
CN112469431A (zh) 2018-07-23 2021-03-09 伊莱利利公司 使用gip/glp1共激动剂用于糖尿病的方法
US11084861B2 (en) 2018-07-23 2021-08-10 Eli Lilly And Company GIP/GLP1 co-agonist compounds
MA53390A (fr) 2018-07-23 2021-06-02 Lilly Co Eli Procédés d'utilisation d'un co-agoniste de gip/glp1 pour une thérapie
US11471512B2 (en) * 2019-03-01 2022-10-18 Merck Sharp & Dohme Llc Pharmaceutical compositions of a peptide
EP4054536A1 (en) 2019-11-07 2022-09-14 Novo Nordisk A/S Solid compositions comprising a glp-1 agonist, an sglt2 inhibitor and a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid
AU2021208601B2 (en) 2020-02-18 2025-06-05 Novo Nordisk A/S Glp-1 compositions and uses thereof
US20230165939A1 (en) 2020-04-29 2023-06-01 Novo Nordisk A/S Solid compositions comprising a glp-1 agonist and histidine
EP4185606A1 (en) * 2020-07-22 2023-05-31 Novo Nordisk A/S Glp-1 and gip receptor co-agonists
PE20231841A1 (es) * 2020-07-22 2023-11-21 Novo Nordisk As Coagonistas de los receptores glp-1 y gip adecuados para el suministro oral
WO2022268213A1 (zh) * 2021-06-25 2022-12-29 甘李药业股份有限公司 含glp-1化合物的药物组合物
KR20230010571A (ko) 2021-07-12 2023-01-19 한미약품 주식회사 Glp-1 유사체를 함유하는 경구 투여 제형 조성물
AU2022312702A1 (en) 2021-07-15 2024-01-18 Novo Nordisk A/S Tablet comprising a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid
CA3223247A1 (en) 2021-07-16 2023-01-19 Thomas Kvistgaard Vilhelmsen Sodium n-(8-(2- hydroxybenzoyl)amino)caprylate polymorphic form a
WO2023065231A1 (en) * 2021-10-21 2023-04-27 Guangzhou Dazhou Biomedicine Ltd. Oral delivery of therapeutic agents
AU2022386166A1 (en) 2021-11-10 2024-06-20 I2O Therapeutics, Inc. Ionic liquid compositions
CN118742326A (zh) * 2021-12-29 2024-10-01 广州大洲生物医药科技有限公司 口服递送
TW202330584A (zh) 2022-01-20 2023-08-01 丹麥商諾佛 儂迪克股份有限公司 前藥及其用途
KR20230132256A (ko) 2022-03-08 2023-09-15 이정열 오징어 조획장치
WO2023191082A1 (ja) 2022-03-31 2023-10-05 株式会社 メドレックス 低溶解性および／または低膜透過性薬物の吸収性が改善された製剤
KR20230147981A (ko) 2022-04-15 2023-10-24 이정열 어류 탈취기
KR20230167546A (ko) 2022-06-02 2023-12-11 이정열 어류 탈취기
EP4545069A1 (en) 2022-06-24 2025-04-30 Sunsho Pharmaceutical Co., Ltd. Pharmaceutical composition and method for producing same
KR20240018118A (ko) 2022-08-02 2024-02-13 이정열 어류 탈취기
WO2024040356A1 (en) * 2022-08-25 2024-02-29 The University Of British Columbia Mucoadhesive pharmaceutical dosage form for unidirectional release of peptide therapeutic particles
KR20240055265A (ko) 2022-10-20 2024-04-29 이정열 어류 탈취기
TW202421645A (zh) * 2022-11-25 2024-06-01 丹麥商諾佛 儂迪克股份有限公司 如ｇｌｐ—１之肽治療劑的口服投與
CN121001710A (zh) 2022-12-30 2025-11-21 阿尔吉法玛公司 提高口服多肽治疗剂的全身生物利用度的组合物和方法
WO2025105840A1 (ko) * 2023-11-17 2025-05-22 (주)인벤티지랩 세마글루타이드 또는 이의 약학적으로 허용 가능한 염을 포함하는 리포좀, 이를 포함하는 약학적 조성물 및 이의 제조 방법
KR20250072883A (ko) 2023-11-17 2025-05-26 (주)인벤티지랩 세마글루타이드 또는 이의 약학적으로 허용 가능한 염을 포함하는 리포좀, 이를 포함하는 약학적 조성물 및 이의 제조 방법
WO2025169190A2 (en) 2024-02-06 2025-08-14 Opko Biologics Ltd. Modified oxyntomodulin and methods of use thereof
KR20250122090A (ko) 2024-02-06 2025-08-13 이정열 어류 탈취기
CN120189496A (zh) * 2024-06-03 2025-06-24 深圳奥礼生物科技有限公司 口服的多肽组合物

Family Cites Families (190)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2059366T3 (es) 1986-03-12 1994-11-16 American Cyanamid Co Compuestos macrolidos.
US5545618A (en) 1990-01-24 1996-08-13 Buckley; Douglas I. GLP-1 analogs useful for diabetes treatment
CA2073856C (en) 1990-01-24 2002-12-03 Douglas I. Buckley Glp-1 analogs useful for diabetes treatment
HUT73494A (en) 1993-03-29 1996-08-28 Univ Cincinnati Analogs of peptide yy and uses thereof
US5705483A (en) 1993-12-09 1998-01-06 Eli Lilly And Company Glucagon-like insulinotropic peptides, compositions and methods
US5968899A (en) 1994-06-03 1999-10-19 Tsumura & Co. Medicinal compositions of peptides with EACA or tranexamic acid for enhanced mucosal absorption
US5512549A (en) 1994-10-18 1996-04-30 Eli Lilly And Company Glucagon-like insulinotropic peptide analogs, compositions, and methods of use
US5574010A (en) 1994-11-14 1996-11-12 The Regents Of The University Of California Treatment of pancreatic tumors with peptide YY and analogs thereof
US5869602A (en) 1995-03-17 1999-02-09 Novo Nordisk A/S Peptide derivatives
US5650386A (en) 1995-03-31 1997-07-22 Emisphere Technologies, Inc. Compositions for oral delivery of active agents
US5866536A (en) 1995-03-31 1999-02-02 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
CN1151836C (zh) 1995-03-31 2004-06-02 艾米斯菲尔技术有限公司 用作传送活性剂的化合物和组合物
SE9600070D0 (sv) 1996-01-08 1996-01-08 Astra Ab New oral pharmaceutical dosage forms
US6268343B1 (en) 1996-08-30 2001-07-31 Novo Nordisk A/S Derivatives of GLP-1 analogs
US6458924B2 (en) 1996-08-30 2002-10-01 Novo Nordisk A/S Derivatives of GLP-1 analogs
JP3149958B2 (ja) 1996-08-30 2001-03-26 ノボ ノルディスク アクティーゼルスカブ Ｇｌｐ―１誘導体
US7235627B2 (en) 1996-08-30 2007-06-26 Novo Nordisk A/S Derivatives of GLP-1 analogs
WO1998020895A1 (en) 1996-11-12 1998-05-22 Novo Nordisk A/S Use of glp-1 peptides
WO1998020885A1 (en) 1996-11-13 1998-05-22 University Of Cincinnati Analogs of peptide yy and uses thereof
US5773647A (en) 1997-02-07 1998-06-30 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
EP0908515A3 (en) 1997-09-16 2000-04-26 Smithkline Beecham Plc Pancreatic polypeptide
AU2610699A (en) 1998-02-27 1999-09-15 Novo Nordisk A/S Derivatives of glp-1 analogs
WO1999043705A1 (en) 1998-02-27 1999-09-02 Novo Nordisk A/S N-terminally truncated glp-1 derivatives
JP2003522099A (ja) 1998-02-27 2003-07-22 ノボ ノルディスク アクティーゼルスカブ 遅延作用プロファイルを有するｇｌｐ−１のｇｌｐ−１誘導体及びエキセンジン
AU2610899A (en) 1998-02-27 1999-09-15 Novo Nordisk A/S N-terminally modified glp-1 derivatives
US6046167A (en) 1998-03-25 2000-04-04 University Of Cincinnati Peptide YY analogs
PE20000564A1 (es) 1998-06-08 2000-07-05 Schering Corp Antagonistas receptores y5 de neuropeptidos
SE9802080D0 (sv) 1998-06-11 1998-06-11 Hellstroem Pharmaceutical composition for the treatment of functional dyspepsia and/or irritable bowel syndrome and new use of substances therein
AU5027299A (en) 1998-07-31 2000-02-28 Novo Nordisk A/S Use of glp-1 and analogues for preventing type ii diabetes
MY155270A (en) 1998-09-24 2015-09-30 Lilly Co Eli Use of glp-1 or analogs in treatment of stroke
WO2000034331A2 (en) 1998-12-07 2000-06-15 Societe De Conseils De Recherches Et D'applications Scientifiques Sas Analogues of glp-1
CA2361716C (en) 1999-02-05 2009-04-28 Emisphere Technologies, Inc. Method of preparing alkylated salicylamides
WO2000048589A1 (en) 1999-02-22 2000-08-24 Emisphere Holdings, Inc. Solid oral dosage form containing heparin or a heparinoid in combination with a carrier
US7658938B2 (en) 1999-02-22 2010-02-09 Merrion Reasearch III Limited Solid oral dosage form containing an enhancer
ES2301477T3 (es) 1999-02-22 2008-07-01 Merrion Research I Limited Forma de dosificacion oral solida que contiene un potenciador.
CA2372214A1 (en) 1999-04-30 2000-11-09 Amylin Pharmaceuticals, Inc. Modified exendins and exendin agonists
US6514500B1 (en) 1999-10-15 2003-02-04 Conjuchem, Inc. Long lasting synthetic glucagon like peptide {GLP-!}
DK1180121T3 (da) 1999-05-17 2004-03-01 Conjuchem Inc Langtidsvirkende insulinotrope peptider
US7601691B2 (en) 1999-05-17 2009-10-13 Conjuchem Biotechnologies Inc. Anti-obesity agents
EP1076066A1 (en) 1999-07-12 2001-02-14 Zealand Pharmaceuticals A/S Peptides for lowering blood glucose levels
US6528486B1 (en) 1999-07-12 2003-03-04 Zealand Pharma A/S Peptide agonists of GLP-1 activity
GB9923436D0 (en) 1999-10-04 1999-12-08 American Home Prod Pharmaceutical compositions
US6793934B1 (en) 1999-12-08 2004-09-21 Shire Laboratories, Inc. Solid oral dosage form
US7262325B2 (en) 2000-06-02 2007-08-28 Emisphere Technologies, Inc. Method of preparing salicylamides
US7049283B2 (en) 2000-12-06 2006-05-23 Novartis Ag Pharmaceutical compositions for the oral delivery of pharmacologically active agents
WO2002046227A2 (en) 2000-12-07 2002-06-13 Eli Lilly And Company Glp-1 fusion proteins
AU2002228608A1 (en) 2000-12-13 2002-06-24 Eli Lilly And Company Amidated glucagon-like peptide-1
EP1390061A2 (en) * 2000-12-13 2004-02-25 Eli Lilly And Company Chronic treatment regimen using glucagon-like insulinotropic peptides
RU2275207C2 (ru) 2000-12-14 2006-04-27 Амилин Фармасьютикалз, Инк. Способ снижения доступности питательного вещества, способ подавления аппетита
GB0102075D0 (en) 2001-01-26 2001-03-14 Astrazeneca Ab Process
US6589938B2 (en) 2001-06-29 2003-07-08 National University Of Singapore Use of angiotensin I derivatives as an agent for the treatment and prevention of infarction-related cardiac injuries and disorders
US20030068356A1 (en) 2001-07-10 2003-04-10 Pather S. Indiran Sequential drug delivery systems
EP2022505B1 (en) 2001-07-31 2011-12-14 The Government of the United States of America, as represented by the Secretary of the Department of Health and Human Services GLP-1, exendin-4, peptide analogs and uses thereof
CN100350968C (zh) 2001-09-24 2007-11-28 皇家创新有限公司 饮食行为的改进
US20040259952A1 (en) 2001-11-29 2004-12-23 Richat Abbas Formulations for oral administration of cromolyn sodium
US8058233B2 (en) 2002-01-10 2011-11-15 Oregon Health And Science University Modification of feeding behavior using PYY and GLP-1
NZ534234A (en) 2002-02-01 2007-05-31 Pfizer Prod Inc Dry granulated formulations of non-dihydrate form of azithromycin
CA2473340C (en) 2002-02-20 2014-12-09 Eli Lilly And Company Formulations comprising a glp-1 compound and a delivery agent, and uses thereof
EP1525219B1 (en) 2002-07-04 2009-05-27 Zealand Pharma A/S Glp-1 and methods for treating diabetes
JP2004131398A (ja) 2002-10-08 2004-04-30 Taihei Chemical Industrial Co Ltd 錠剤用滑沢剤
EP1583549A4 (en) 2003-01-17 2006-10-04 Sod Conseils Rech Applic YY PEPTIDE ANALOGS
US20050059605A1 (en) 2003-01-31 2005-03-17 Krishna Peri Chemically modified metabolites of regulatory peptides and methods of producing and using same
EA009366B1 (ru) 2003-03-19 2007-12-28 Эли Лилли Энд Компани Связанные с полиэтиленгликолем соединения гпп-1
JP2006528982A (ja) 2003-05-14 2006-12-28 エミスフェアー・テクノロジーズ・インク ペプチドｙｙおよびｐｙｙ作用薬の送達用組成物
US7572581B2 (en) 2003-06-30 2009-08-11 Roche Molecular Systems, Inc. 2′-terminator nucleotide-related methods and systems
PT1651248E (pt) 2003-07-11 2009-11-10 Novartis Ag Composições farmacêuticas para dose oral compreendendo um agente de administração na forma micronizada
EP1653996A2 (en) 2003-08-08 2006-05-10 Novo Nordisk Health Care AG Use of galactose oxidase for selective chemical conjugation of protractor molecules to proteins of therapeutic interest
CN100444898C (zh) 2003-09-19 2008-12-24 诺沃挪第克公司 治疗肽的清蛋白结合型衍生物
EP1667724A2 (en) 2003-09-19 2006-06-14 Novo Nordisk A/S Albumin-binding derivatives of therapeutic peptides
KR101241862B1 (ko) 2003-09-19 2013-03-13 노보 노르디스크 에이/에스 신규 ｇｌｐ-1 유도체
CN102784386A (zh) 2003-11-20 2012-11-21 诺沃挪第克公司 对于生产和用于注射装置中是最佳的含有丙二醇的肽制剂
MXPA06006746A (es) 2003-12-18 2006-08-18 Novo Nordisk As Analogos de glp-1 novedosos ligados a agentes similares a albumina.
AU2004298424A1 (en) 2003-12-18 2005-06-30 Novo Nordisk A/S Novel GLP-1 compounds
US20060286129A1 (en) 2003-12-19 2006-12-21 Emisphere Technologies, Inc. Oral GLP-1 formulations
WO2005077072A2 (en) 2004-02-11 2005-08-25 Amylin Pharmaceuticals, Inc. Hybrid polypeptides with selectable properties
WO2005077094A2 (en) 2004-02-11 2005-08-25 Amylin Pharmaceuticals, Inc. Pancreatic polypeptide family motifs and polypeptides comprising the same
WO2005089789A2 (en) 2004-03-17 2005-09-29 7Tm Pharma A/S Y2 selective receptor agonists for therapeutic interventions
GB2427551B (en) 2004-03-17 2007-05-30 7Tm Pharma As Y4 selective receptor agonists for therapeutic interventions
US20090186811A1 (en) 2004-03-17 2009-07-23 Thue Schwartz Y2 Selective Receptor Agonists for Therapeutic Interventions
CA2560166A1 (en) 2004-03-17 2005-09-29 7Tm Pharma A/S Y2/y4 selective receptor agonists for therapeutic interventions
WO2005099672A1 (en) 2004-04-13 2005-10-27 Ranbaxy Laboratories Limited A modified release pharmaceutical formulation comprising amoxicillin and clavulanate
JP4903690B2 (ja) 2004-05-06 2012-03-28 エミスフェアー・テクノロジーズ・インク Ｎ−［８−（２−ヒドリキシベンゾイル）アミノ］カプリル酸一ナトリウムの結晶多形体
NZ550894A (en) 2004-05-06 2011-02-25 Emisphere Tech Inc Solid dosage form of wetted heparin
US8273794B2 (en) 2004-05-14 2012-09-25 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
GB0412181D0 (en) 2004-06-01 2004-06-30 Celltech R&D Ltd Biological products
WO2005121090A1 (en) 2004-06-02 2005-12-22 Abbott Laboratories Substituted piperidines that have antiangiogenic activity
US20070021346A1 (en) 2005-05-26 2007-01-25 Ewing William R N-terminally modified GLP-1 receptor modulators
CN101010339B (zh) 2004-07-02 2011-11-09 布里斯托尔-迈尔斯斯奎布公司 人类胰高血糖素样肽-1调节剂及它们在治疗糖尿病及相关病况中的用途
TW200611704A (en) 2004-07-02 2006-04-16 Bristol Myers Squibb Co Human glucagon-like-peptide-1 modulators and their use in the treatment of diabetes and related conditions
EP2289560B1 (en) 2004-07-08 2015-04-22 Novo Nordisk A/S Polypeptide protracting tags comprising a tetrazole moiety
CN105708787A (zh) 2004-07-12 2016-06-29 爱密斯菲尔科技公司 用于递送肽yy和pyy激动剂的组合物
WO2006020207A2 (en) 2004-07-19 2006-02-23 University Of Cincinnati Compounds for control of appetite
JP2008509933A (ja) 2004-08-13 2008-04-03 エミスフェアー・テクノロジーズ・インク 送達剤のマイクロ粒子またはナノ粒子を含む医薬製剤
WO2006049681A2 (en) 2004-08-30 2006-05-11 Bayer Pharmaceuticals Corporation Selective neuropeptide y2 receptor agonists
US7893017B2 (en) 2004-10-07 2011-02-22 Novo Nordisk A/S Protracted GLP-1 compounds
US7410949B2 (en) 2005-01-18 2008-08-12 Hoffmann-La Roche Inc. Neuropeptide-2 receptor (Y-2R) agonists and uses thereof
EP1843755B1 (en) 2005-02-01 2015-04-01 Emisphere Technologies, Inc. Gastric retention and controlled release delivery system
EP2256130B1 (en) 2005-02-02 2013-09-25 Novo Nordisk A/S Novel insulin derivatives
WO2006096515A2 (en) 2005-03-04 2006-09-14 Biorexis Pharmaceutical Corporation Modified transferrin fusion proteins
GB0504857D0 (en) 2005-03-09 2005-04-13 Imp College Innovations Ltd Novel compounds and their effects on feeding behaviour
TWI372629B (en) 2005-03-18 2012-09-21 Novo Nordisk As Acylated glp-1 compounds
WO2006097535A2 (en) 2005-03-18 2006-09-21 Novo Nordisk A/S Peptide agonists of the glucagon family with secretin like activity
WO2006097538A1 (en) 2005-03-18 2006-09-21 Novo Nordisk A/S Extended glp-1 compounds
WO2006097536A2 (en) 2005-03-18 2006-09-21 Novo Nordisk A/S Dimeric peptide agonists of the glp-1 receptor
EP1863449A2 (en) 2005-03-28 2007-12-12 Dexcel Pharma Technologies Ltd. Controlled absorption of statins in the intestine
WO2007008778A2 (en) 2005-07-11 2007-01-18 Nastech Pharmaceutical Company Inc. Formulations for enhanced mucosal delivery of pyy
WO2007011958A2 (en) 2005-07-15 2007-01-25 Emisphere Technologies, Inc. Intraoral dosage forms of glucagon
BRPI0613984A2 (pt) 2005-07-18 2011-03-01 Novo Nordisk As peptìdios para uso no tratamento da obesidade, seu uso e composição farmacêutica compreendendo os mesmos
WO2007024700A2 (en) 2005-08-19 2007-03-01 Amylin Pharmaceuticals, Inc. Exendin for treating diabetes and reducing body weight
US20070049557A1 (en) 2005-08-24 2007-03-01 Hashim Ahmed Solid pharmaceutical dosage forms comprising bisphosphonates and modified amino acid carriers
CN101268096A (zh) 2005-09-21 2008-09-17 7Tm制药联合股份有限公司 用于治疗性干预的y2选择性受体激动剂
CA2623088A1 (en) 2005-09-21 2007-04-12 7Tm Pharma A/S Y4 selective receptor agonists for therapeutic interventions
WO2007061434A2 (en) 2005-11-10 2007-05-31 Nastech Pharmaceutical Company Inc. A pharmaceutical formulation of glp-1 and its use for treating a metabolic syndrome
BRPI0618723A2 (pt) 2005-11-17 2011-09-06 Novartis Ag composição farmacêutica oral na forma de um comprimido prensado
ATE549350T1 (de) 2005-12-07 2012-03-15 Hoffmann La Roche Neuropeptid-2-rezeptor-agonisten
US20080318861A1 (en) 2005-12-08 2008-12-25 Nastech Pharmaceutical Company Inc. Mucosal Delivery of Stabilized Formulations of Exendin
EP1963343A1 (en) 2005-12-14 2008-09-03 Novo Nordisk A/S Polypeptide protracting tags
US20070197445A1 (en) 2006-01-18 2007-08-23 University Of Cincinnati Compounds for control of appetite
WO2007109354A2 (en) 2006-03-21 2007-09-27 Amylin Pharmaceuticals, Inc. Peptide-peptidase inhibitor conjugates and methods of using same
US7704977B2 (en) 2006-04-07 2010-04-27 Merrion Research Iii Limited Solid oral dosage form containing an enhancer
WO2007121318A2 (en) 2006-04-12 2007-10-25 Emisphere Technologies, Inc. Formulations for delivering insulin
MX2008014061A (es) 2006-05-09 2008-11-14 Novo Nordisk As Derivado de insulina.
US20070292512A1 (en) 2006-06-09 2007-12-20 Merrion Research Ii Limited Solid Oral Dosage Form Containing an Enhancer
US9364502B2 (en) 2006-06-28 2016-06-14 Emisphere Technologies, Inc. Gallium nitrate formulations
GB0613196D0 (en) 2006-07-03 2006-08-09 Imp Innovations Ltd Novel compounds and their effects on feeding behaviour
ES2296529B1 (es) 2006-08-07 2009-04-01 Laboratorios Farmaceuticos Rovi, S.A. Composicion farmaceutica con promotores de absorcion.
CN101506147B (zh) 2006-09-07 2012-03-21 霍夫曼-拉罗奇有限公司 用于制备snac（n-（8-[2-羟基苯甲酰基]-氨基）辛酸钠）的方法
JO2945B1 (en) * 2006-09-13 2016-03-15 سميث كلاين بيتشام كوربوريشن Methods of giving prolonged hypoglycemic agents
EP2074141B1 (en) 2006-09-22 2016-08-10 Novo Nordisk A/S Protease resistant insulin analogues
AR062925A1 (es) 2006-09-22 2008-12-17 Novartis Ag Metodo para fabricar tabletas que contienen agentes farmacologicamente activos
GB0621973D0 (en) 2006-11-03 2006-12-13 Philogen Spa Binding molecules and uses thereof
WO2008070547A1 (en) 2006-12-01 2008-06-12 Emisphere Technologies Inc. Improved acyclovir formulations
US20090099074A1 (en) 2007-01-10 2009-04-16 Conjuchem Biotechnologies Inc. Modulating food intake
US20100022446A1 (en) 2007-01-18 2010-01-28 Novo Nordisk A/S Use of Peptides in Combination with Surgical Intervention for the Treatment of Obesity
US20100016237A1 (en) 2007-01-18 2010-01-21 Novo Nordisk A/S Novel Peptides for Use in the Treatment of Obesity
ATE507818T1 (de) 2007-03-02 2011-05-15 Novartis Ag Orale verabreichung eines calcitonins
GB0708226D0 (en) 2007-04-27 2007-06-06 7Tm Pharma As Y-receptor agonists
EP2171080A4 (en) 2007-06-12 2010-10-27 Glaxosmithkline Llc PROCESS FOR DETECTING PROTEIN IN PLASMA
CN101970475A (zh) 2007-07-09 2011-02-09 帝国改革有限公司 人类胰多肽(hpp)类似物及其对摄食行为的作用
US20110183889A1 (en) 2007-08-29 2011-07-28 The Regents Of The University Of California Salicylanilide modified peptides for use as oral therapeutics
EP2190872B1 (en) 2007-09-05 2018-03-14 Novo Nordisk A/S Glucagon-like peptide-1 derivatives and their pharmaceutical use
EP2190873B1 (en) 2007-09-05 2015-07-22 Novo Nordisk A/S Truncated glp-1 derivatives and their therapeutical use
EP2190460B1 (en) 2007-09-05 2014-12-17 Novo Nordisk A/S Peptides derivatized with a-b-c-d- and their therapeutical use
RU2010113986A (ru) 2007-09-11 2011-10-20 Мондобайотек Лабораториз Аг (Li) Применение пептида в качестве терапевтического средства
EP2195034A2 (en) 2007-09-27 2010-06-16 Amylin Pharmaceuticals, Inc. Peptide-peptidase inhibitor conjugates and methods of making and using same
PL2203181T3 (pl) 2007-10-16 2018-07-31 Biocon Limited Podawana doustnie stała kompozycja farmaceutyczna i jej sposób
PL2215047T3 (pl) 2007-11-02 2014-05-30 Emisphere Tech Inc Sposób leczenia niedoborów witaminy b12
US20090124639A1 (en) 2007-11-06 2009-05-14 Emisphere Technologies Inc. valacyclovir formulations
US20100317057A1 (en) 2007-12-28 2010-12-16 Novo Nordisk A/S Semi-recombinant preparation of glp-1 analogues
WO2009138511A1 (en) 2008-05-16 2009-11-19 Novo Nordisk A/S Long-acting y2 and/or y4 receptor agonists
CA2734442C (en) 2008-08-18 2016-08-16 Oramed Ltd Methods and compositions for oral administration of proteins
US8637647B2 (en) 2008-09-12 2014-01-28 Novo Nordisk A/S Method of acylating a peptide or protein
US8299023B2 (en) 2008-09-17 2012-10-30 Hoffmann-La Roche Inc. Neuropeptide-2 receptor (Y-2R) agonists
GB0817067D0 (en) 2008-09-18 2008-10-22 7Tm Pharma As Intestinal treatment
EP2386203B1 (de) 2008-10-15 2013-11-20 Bayer CropScience AG Verwendung von Dithiin-tetracarboximiden zum Bekämpfen phytopathogener Pilze
MX2011004427A (es) 2008-11-05 2011-05-31 Hoffmann La Roche Agonistas del receptor de neuropeptido-2 (y-2r) y usos de los mismos.
CN101463081B (zh) 2009-01-12 2012-07-04 华东师范大学 一种glp-1衍生物
NZ594044A (en) 2009-02-13 2014-08-29 Boehringer Ingelheim Int Antidiabetic medications comprising a dpp-4 inhibitor (linagliptin) optionally in combination with other antidiabetics
JP5584236B2 (ja) 2009-02-20 2014-09-03 イプセン ファルマ ソシエテ パール アクシオン サンプリフィエ 神経ペプチドｙ受容体結合化合物を有する細胞毒性コンジュゲート
AR077956A1 (es) 2009-09-14 2011-10-05 Bayer Cropscience Ag Combinaciones de compuestos activos
EP2477643A1 (en) 2009-09-18 2012-07-25 Novo Nordisk A/S Long-acting y2 receptor agonists
JP2013507414A (ja) 2009-10-13 2013-03-04 エフ．ホフマン−ラ ロシュ アーゲー 神経ペプチド−２受容体（ｙ−２ｒ）アゴニスト
JP2013510829A (ja) 2009-11-13 2013-03-28 ノヴォ ノルディスク アー／エス 長時間作用型ｙ２受容体アゴニスト
CA2784120A1 (en) 2009-12-16 2011-07-14 Nod Pharmaceuticals, Inc. Compositions and methods for oral drug delivery
JP2013514322A (ja) * 2009-12-16 2013-04-25 ノヴォ ノルディスク アー／エス 修飾されたｎ末端を有するｇｌｐ−１受容体アゴニスト化合物
US20110182985A1 (en) 2010-01-28 2011-07-28 Coughlan David C Solid Pharmaceutical Composition with Enhancers and Methods of Preparing thereof
WO2011109787A1 (en) 2010-03-05 2011-09-09 Conjuchem, Llc Methods of administering insulinotropic peptides
GB2478849A (en) 2010-03-16 2011-09-21 Chiasma Inc Improved pharmecutical compositions and methods of delivery
US9040660B2 (en) 2010-04-20 2015-05-26 Novo Nordisk A/S Long-acting gastrin derivatives
EP2565202A4 (en) * 2010-04-30 2013-10-30 Sanwa Kagaku Kenkyusho Co PEPTIDE FOR IMPROVING THE IN VIVO STABILITY OF A PHYSIOLOGICALLY ACTIVE SUBSTANCE OR ANALOGUES AND PHYSIOLOGICALLY ACTIVE SUBSTANCE AND ANALOGUES HAVING IN VIVO STABILITY IMPROVEMENT
KR101819609B1 (ko) 2010-05-05 2018-01-17 베링거 인겔하임 인터내셔날 게엠베하 체중 감소 치료에 후속하는 dpp-4 억제제에 의한 순차적 병용 요법
DE202010015867U1 (de) 2010-11-25 2011-05-05 Buchhalter, Thomas Elektromechanische Halterung zur Aufnahme von Navigations- und Kommunikationsgeräte im KFZ
PL3326620T3 (pl) 2010-12-16 2020-08-24 Novo Nordisk A/S Kompozycje stałe zawierające agonistę glp-1 i sól kwasu n-(8-(2- hydroksybenzoilo)amino)kaprylowego
GB201101459D0 (en) 2011-01-27 2011-03-16 Imp Innovations Ltd Novel compounds and thier effects on fedding behaviour
BR112013026195A2 (pt) 2011-04-12 2016-11-29 Novo Nordisk As derivados de glp-1 duplamente acilados
CN104271588B (zh) 2011-07-08 2017-10-10 安米林药品有限责任公司 具有增强的作用持续时间和降低的免疫原性的工程改造的多肽
HUE062740T2 (hu) * 2012-03-22 2023-12-28 Novo Nordisk As GLP-1 peptidek készítményei és elõállításuk
DK2827845T3 (en) 2012-03-22 2019-04-01 Novo Nordisk As COMPOSITIONS INCLUDING A PROCEDURE AND PREPARING THEREOF
CN111494323B (zh) 2012-03-22 2023-03-28 诺和诺德股份有限公司 包含递送剂的组合物及其制备
WO2013178490A1 (en) 2012-05-29 2013-12-05 Novo Nordisk A/S Pancreatic polypeptide compounds and use
US9993430B2 (en) * 2012-06-20 2018-06-12 Novo Nordisk A/S Tablet formulation comprising semaglutide and a delivery agent
DK2866825T3 (da) 2012-07-01 2020-06-08 Novo Nordisk As Anvendelse af langstidsvirkende glp-1-peptider
PT2991671T (pt) * 2013-05-02 2018-11-05 Novo Nordisk As Dosagem oral de compostos de glp-1
RU2015144632A (ru) 2013-05-02 2017-06-07 Глаксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед Терапевтические пептиды
EP3068795B1 (en) 2013-11-15 2019-03-06 Novo Nordisk A/S Hpyy(1-36) having a beta-homoarginine substitution at position 35
KR20160075819A (ko) 2013-11-15 2016-06-29 노보 노르디스크 에이/에스 선택적 pyy 화합물 및 그것의 사용
WO2016128971A1 (en) 2015-02-09 2016-08-18 Entera Bio Ltd. Treatment of bone fractures and defects
CN107849110B (zh) 2015-06-12 2021-11-26 诺和诺德股份有限公司 选择性pyy化合物及其用途
AU2016335287A1 (en) 2015-10-07 2018-04-12 Cyprumed Gmbh Pharmaceutical formulations for the oral delivery of peptide drugs
SG11202006595RA (en) 2018-02-02 2020-08-28 Novo Nordisk As Solid compositions comprising a glp-1 agonist, a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid and a lubricant

Also Published As

Publication number Publication date
US20190216739A1 (en) 2019-07-18
EP2991671A1 (en) 2016-03-09
US12239739B2 (en) 2025-03-04
MX2018012166A (es) 2020-09-02
US10278923B2 (en) 2019-05-07
KR20160002945A (ko) 2016-01-08
KR102272671B1 (ko) 2021-07-06
EP3485900A1 (en) 2019-05-22
WO2014177683A1 (en) 2014-11-06
ZA201507096B (en) 2020-01-29
BR112015026325A2 (pt) 2017-07-25
ZA201806791B (en) 2019-06-26
RS58039B1 (sr) 2019-02-28
HUE040609T2 (hu) 2019-03-28
PL2991671T3 (pl) 2019-01-31
AU2014261336B2 (en) 2019-02-28
SI2991671T1 (sl) 2018-10-30
JP2016519128A (ja) 2016-06-30
HRP20181393T1 (hr) 2018-11-02
MX2019013123A (es) 2019-12-05
AU2014261336A1 (en) 2015-10-08
EP2991671B1 (en) 2018-08-15
US20250262159A1 (en) 2025-08-21
CA2910903A1 (en) 2014-11-06
KR20180115814A (ko) 2018-10-23
MX2015015009A (es) 2016-03-09
US20160067184A1 (en) 2016-03-10
IL241813A (en) 2017-12-31
RU2671406C2 (ru) 2018-10-31
US20170312225A1 (en) 2017-11-02
JP6672140B2 (ja) 2020-03-25
DK2991671T3 (en) 2018-10-08
RU2015147876A (ru) 2017-06-06
LT2991671T (lt) 2018-09-25
JP7576910B2 (ja) 2024-11-01
MY172578A (en) 2019-12-03
ES2688462T3 (es) 2018-11-02
SA515370075B1 (ar) 2017-08-27
PT2991671T (pt) 2018-11-05
MX369259B (es) 2019-11-04
CY1120730T1 (el) 2019-12-11
KR20210086717A (ko) 2021-07-08
JP2020073533A (ja) 2020-05-14
US20250213485A1 (en) 2025-07-03

Similar Documents

Publication Publication Date Title
ZA201806791B (en) Oral dosing of glp-1 compounds
GB201322602D0 (en) Pharmaceutical compounds
GB201306610D0 (en) Pharmaceutical compounds
ZA201508675B (en) Stable oral solutions for combined api
ZA201602047B (en) Pharmaceutical compounds
GB201312386D0 (en) Pharmaceutical compounds
EP2948129A4 (en) THERAPEUTIC COMPOUNDS
HUE041421T2 (hu) Tiacumicin vegyületeket tartalmazó készítmény
GB201305103D0 (en) An oral dosage form
GB201314286D0 (en) Therapeutic Compounds
GB201312499D0 (en) Therapeutic compounds
GB201413253D0 (en) Solid dosage form
GB2520315B (en) Oral Syringes
GB201407847D0 (en) Composition for the oral delivery of compounds
GB201320905D0 (en) Therapeutic compounds
GB201317166D0 (en) Pharmaceutical compounds
GB201314397D0 (en) Therapeutic Compounds
GB201311169D0 (en) Therapeutic compounds
GB201316780D0 (en) Pharmaceutical compounds
GB201316791D0 (en) Pharmaceutical Compounds
GB201315734D0 (en) Pharmaceutical compounds
GB201315733D0 (en) Pharmaceutical compounds
GB201312464D0 (en) Pharmaceutical compounds
GB201308781D0 (en) Pharmaceutical compounds
GB201308780D0 (en) Pharmaceutical compounds